文献速递白血病

巩固治疗后可测量残留病结果对儿童急性淋巴细胞白血病是否有用

Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?
PubMed 文献 · Leukemia · 2024-09-10

研究纳入DCOG-ALL-10(n=271)和DCOG-ALL-9(n=122)中危、巩固治疗结束(EOC)时MRD<0.05%的儿童ALL患者,分析EOC后MRD检测的临床意义。EOC MRD阴性者后续MRD结果不影响结局,6年累积复发率(6-y CIR)后续全阴性7.4% vs 至少一次阳性3.8%(p=0.51);EOC MRD阳性但后续转阴者6-y CIR 7.0%;EOC及后续均阳性者6-y CIR 29.4%(p<0.001),验证队列及更新EuroMRD指南后结果一致。

要点

  • EOC MRD阴性患者后续MRD检测可放弃,后续阳性与否6-y CIR无显著差异(7.4% vs 3.8%,p=0.51)。
  • EOC MRD阳性但后续转阴者预后良好,6-y CIR 7.0%。
  • EOC及后续均MRD阳性者复发风险高,6-y CIR 29.4%,后续检测可能有助于风险分层。

核心结论

  • EOC MRD阴性患者后续MRD检测可放弃;EOC MRD阳性患者后续MRD检测可能有助于进一步风险分层。

研究设计与样本

  • 研究纳入DCOG-ALL-10(n=271)和DCOG-ALL-9(n=122)中危儿童ALL患者,均EOC时MRD<0.05%。
  • EOC MRD阴性患者178例,EOC MRD阳性患者91例(其中后续转阴43例,后续至少一次阳性48例)。

主要发现

  • EOC MRD阴性患者中,后续所有时间点MRD阴性者6-y CIR 7.4%(95% CI,3.9%-12.3%),至少一个后续时间点阳性者6-y CIR 3.8%(95% CI,0.3%-16.8%),p=0.51。
  • EOC MRD阳性但后续转阴者6-y CIR 7.0%(95% CI,1.8%-17.2%)。
  • EOC MRD阳性且后续至少一个时间点阳性者6-y CIR 29.4%(95% CI,17.2%-42.8%),p<0.001。
  • 上述结果在ALL-9验证队列及使用更新EuroMRD指南后得到证实。

关键数值与推荐

  • EOC MRD阴性患者后续所有时间点阴性6-y CIR 7.4%(95% CI,3.9%-12.3%)vs 至少一个后续时间点阳性3.8%(95% CI,0.3%-16.8%),p=0.51。
  • EOC MRD阳性且后续转阴者6-y CIR 7.0%(95% CI,1.8%-17.2%)。
  • EOC MRD阳性且后续至少一个时间点阳性者6-y CIR 29.4%(95% CI,17.2%-42.8%),p<0.001。

临床怎么用

  • 作者认为EOC MRD阴性患者后续MRD检测可放弃。
  • 作者认为EOC MRD阳性患者后续MRD检测可能有助于进一步风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Measurable residual disease (MRD) is regularly tested at later timepoints after the end of first consolidation (EOC) in children with acute lymphoblastic leukemia (ALL). The question remains whether this is useful for detecting (molecular) relapse. We investigated the clinical relevance of MRD after EOC in intermediate risk patients treated on DCOG-ALL-10 (n = 271) and DCOG-ALL-9 (n = 122), with MRD <0.05% at EOC. EOC MRD-negative patients (n = 178) had excellent outcomes, irrespective of MRD results at later timepoints; 6-year cumulative incidence of relapse (6-y CIR) of 7.4% (95% CI, 3.9%-12.3%) for those with MRD negativity at all later timepoints compared to 3.8% (95% CI, 0.3%-16.8%) for those with one or more later timepoints being positive (p = 0.51). Patients with positive EOC MRD (n = 91) of whom the subsequent timepoints were MRD negative (n = 43), had comparable good outcomes, 6-y CIR of 7.0% (95% CI, 1.8%-17.2%). In contrast, patients being MRD positive at EOC and MRD positive at one or more subsequent timepoints (n = 48) had a higher risk of relapse, 6-y CIR 29.4% (95% CI, 17.2%-42.8%), p < 0.001. These findings were confirmed in the validation cohort of ALL-9 as well as using the updated EuroMRD guidelines. In EOC MRD-negative patients, subsequent MRD measurements can be abandoned. For EOC MRD-positive patients the subsequent MRD measurement might be informative for further risk stratification.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Stutterheim J, van der Waarden R, de Groot-Kruseman HA, et al. Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia? Leukemia. 2024. PMID: 39256602. doi:10.1038/s41375-024-02386-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。